Page last updated: 2024-11-04

tazarotene and Dermatitis

tazarotene has been researched along with Dermatitis in 2 studies

tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.

Dermatitis: Any inflammation of the skin.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sugarman, JL1
Weiss, J1
Tanghetti, EA1
Bagel, J1
Yamauchi, PS1
Stein Gold, L1
Lin, T1
Martin, G1
Pillai, R1
Israel, R1
Resnik, KS1
Kutzner, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet[NCT04720105]Phase 422 participants (Actual)Interventional2020-11-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Dermatology Quality of Life Index (DLQI)

Patient-reported outcomes evaluated by Dermatology Quality of Life Index (DLQI). DLQi is a 10-item questionnaire, each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24

Interventionscore on a scale (Mean)
BaselineWeek 24
Participants With Plaque Type Psoriasis6.244.94

Numerical Rating Scale (NRS)

Treatment satisfaction evaluated by a Numerical Rating Scale (NRS). Full scale from 0 to 10, higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24

Interventionscore on a scale (Mean)
BaselineWeek 24
Participants With Plaque Type Psoriasis1.351.29

Palmoplantar Physician Global Assessment (ppPGA)

Number of participants achieving Palmoplantar Physician Global Assessment (ppPGA) of 0 (clear) or 1 (almost clear/minimal) after 24 weeks of treatment. The ppPGA is based on the Investigators Global Assessment (IGA) modified version 11, specifically applied to the hands and/or feet: 0 (clear), 1 (almost clear/minimal), 2 (mild), 3 (moderate), 4 (marked/moderate-to-severe), 5 (severe) (NCT04720105)
Timeframe: Baseline and Week 24

Interventionscore on a scale (Mean)
BaselineWeek 24
Participants With Plaque Type Psoriasis3.472.24

Reviews

1 review available for tazarotene and Dermatitis

ArticleYear
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
    Journal of drugs in dermatology : JDD, 2018, Aug-01, Volume: 17, Issue:8

    Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations;

2018

Other Studies

1 other study available for tazarotene and Dermatitis

ArticleYear
Mimicry illuminating pitfalls in histopathologic diagnosis: nutritional deficiency-like dermatitis secondary to topical tazarotene and keratoacanthomatous pseudocarcinomatous hyperplasia in CD30+ lymphoproliferative disorder as illustrative.
    The American Journal of dermatopathology, 2009, Volume: 31, Issue:1

    Topics: Adolescent; Child; Dermatitis; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Hyperpl

2009